Functional Analysis of Activins During Development
发育过程中激活蛋白的功能分析
基本信息
- 批准号:7409195
- 负责人:
- 金额:$ 31.47万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1994
- 资助国家:美国
- 起止时间:1994-08-17 至 2010-09-27
- 项目状态:已结题
- 来源:
- 关键词:ACVR2 geneACVR2B geneAblationActivinsAdultApoptosisAppendixBMP4BMP7 geneBMPR2 geneBindingBinding ProteinsBiochemicalBiologicalBirthBone Morphogenetic ProteinsCell NucleusComplexDataDefectDevelopmentDifferentiation and GrowthDiseaseEmbryoExencephaliesFamilyFamily memberFemaleFertilityFollicle Stimulating HormoneFollistatinGDF9 geneGene ExpressionGene Expression ProfileGenerationsGenesGeneticGenetic ModelsGrantGrowthGrowth Differentiation Factor 9Growth FactorHeart failureHeterodimerizationHeterozygoteHomozygoteHourHumanIn VitroIndividualInfertilityKnock-outKnockout MiceLaboratoriesLeftLifeLigandsLiverMADH2 geneMADH3 geneMADH4 geneMADH6 geneMADH7 geneMalignant neoplasm of ovaryMammalsManuscriptsMediatingMeiosisModelingMusMuscleMutant Strains MiceMutateMutationNewborn InfantOocytesOvarianOvarian Granulosa CellOvaryPathway interactionsPhenotypePhosphorylationPhysiological ProcessesPhysiologyPlayPolycystic Ovary SyndromePremature Ovarian FailureProteinsReceptor ActivationReceptor Serine/Threonine KinaseReproductionReproductive PhysiologyResearch PersonnelRoleSecondary toSignal PathwaySignal TransductionSignaling ProteinSkinStagingStructure of primordial sex cellSystemTacrolimus Binding ProteinsTestingTissuesTransforming Growth Factor betaTransforming Growth FactorsTransgenic MiceTransgenic ModelType II Activin ReceptorsVentricularWomanactivin Aactivin Bbasebody systembone morphogenetic protein receptor type Ibone morphogenetic protein receptor type IIcell growthcell typecraniofacialdosageextracellularfolliculogenesisgene functiongranulosa cellin vivoinhibinintraovarianmalemouse modelpostnatalprogramsreceptorreceptor bindingrecombinasereproductiveresponsetooltranscription factor
项目摘要
DESCRIPTION (provided by applicant): The transforming growth factor beta (TGFbeta) superfamily is the largest family of secreted proteins in mammals. This family includes the activins, inhibins, TGFbetas, bone morphogenetic proteins (BMPs), and growth differentiation factors (GDFs). These ligands signal through an oligomeric complex of transmembrane type I and type II serine/threonine kinase receptors. Ligand-induced heterodimerization of these receptors leads to phosphorylation of receptor-regulated SMAD proteins, which translocate to the nucleus with the common SMAD4 protein and regulate gene expression. The characterization of mice and humans with mutations in these signaling pathways has revealed the diversity of developmental and physiological processes in which this family functions. Through the support of this grant, my laboratory has generated and analyzed mice with mutations in activin subunits, an activin binding protein (follistatin), activin receptor type II, a downstream receptor binding protein (FKBP 12), and SMADS. We have recently shown that mice with granulosa cell ablation of follistatin are a model for premature ovarian failure in women. The utility of these knockout mice in defining gene function in vivo is unparalleled, and these powerful genetic models have been indispensable for investigating development and reproduction. The overall hypothesis of this R01 renewal is that we will be able to dissect the TGFbeta signaling pathways in the ovary using available and newly-created ovary-specific knockout mouse models. These studies will allow us to place ligands, receptors, and downstream SMAD proteins into biological pathways in a single cell type (i.e., The granulosa cells of the ovary). The Specific Aims of the proposed studies are as follows: 1) Produce transgenic models to define the intraovarian roles of activins; 2) Dissect the activin receptor type II, BMP receptor type II, and BMP receptor type I signaling pathways in the ovary; and 3) Study the interrelationships of the downstream SMAD proteins in ovarian physiology. Generation and characterization of these transgenic mice will define essential and interacting TGFa superfamily signaling components and pathways in the ovary and will continue to be important models for human reproductive diseases including infertility, premature ovarian failure, polycystic ovary syndrome, and ovarian cancer.
描述(由申请人提供):转化生长因子β(TGFbeta)超家族是哺乳动物中最大的分泌蛋白家族。该家族包括激活素、抑制素、TGFbeta、骨形态发生蛋白 (BMP) 和生长分化因子 (GDF)。这些配体通过 I 型和 II 型跨膜丝氨酸/苏氨酸激酶受体的寡聚复合物发出信号。配体诱导的这些受体的异二聚化导致受体调节的 SMAD 蛋白磷酸化,该蛋白与常见的 SMAD4 蛋白一起易位到细胞核并调节基因表达。这些信号通路突变的小鼠和人类的特征揭示了该家族功能的发育和生理过程的多样性。通过这笔资助的支持,我的实验室已经生成并分析了激活素亚基、激活素结合蛋白(卵泡抑素)、激活素受体 II 型、下游受体结合蛋白 (FKBP 12) 和 SMADS 突变的小鼠。我们最近发现,颗粒细胞去除卵泡抑素的小鼠是女性卵巢早衰的模型。这些基因敲除小鼠在体内定义基因功能方面的效用是无与伦比的,这些强大的遗传模型对于研究发育和繁殖是不可或缺的。 R01 更新的总体假设是,我们将能够使用现有的和新创建的卵巢特异性敲除小鼠模型来剖析卵巢中的 TGFbeta 信号通路。这些研究将使我们能够将配体、受体和下游 SMAD 蛋白放入单一细胞类型(即卵巢的颗粒细胞)的生物途径中。拟议研究的具体目标如下: 1)产生转基因模型来定义激活素的卵巢内作用; 2)剖析卵巢中的激活素受体II型、BMP受体II型、BMP受体I型信号通路; 3) 研究下游SMAD蛋白在卵巢生理学中的相互关系。这些转基因小鼠的产生和表征将定义卵巢中重要且相互作用的 TGFα 超家族信号传导成分和途径,并将继续成为人类生殖疾病(包括不孕症、卵巢早衰、多囊卵巢综合征和卵巢癌)的重要模型。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MARTIN M. MATZUK其他文献
MARTIN M. MATZUK的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MARTIN M. MATZUK', 18)}}的其他基金
Kinases as Therapeutic Targets for Endometriosis
激酶作为子宫内膜异位症的治疗靶点
- 批准号:
10674987 - 财政年份:2022
- 资助金额:
$ 31.47万 - 项目类别:
Kinases as Therapeutic Targets for Endometriosis
激酶作为子宫内膜异位症的治疗靶点
- 批准号:
10532966 - 财政年份:2022
- 资助金额:
$ 31.47万 - 项目类别:
Disruption of semen liquefaction using specific KLK3 inhibitors as a new contraceptive
使用特定 KLK3 抑制剂作为新避孕药破坏精液液化
- 批准号:
10682061 - 财政年份:2022
- 资助金额:
$ 31.47万 - 项目类别:
Disruption of semen liquefaction using specific KLK3 inhibitors as a new contraceptive
使用特定 KLK3 抑制剂作为新避孕药破坏精液液化
- 批准号:
10764639 - 财政年份:2022
- 资助金额:
$ 31.47万 - 项目类别:
Disruption of semen liquefaction using specific KLK3 inhibitors as a new contraceptive
使用特定 KLK3 抑制剂作为新避孕药破坏精液液化
- 批准号:
10598585 - 财政年份:2022
- 资助金额:
$ 31.47万 - 项目类别:
Disruption of semen liquefaction using specific KLK3 inhibitors as a new contraceptive
使用特定 KLK3 抑制剂作为新避孕药破坏精液液化
- 批准号:
10419647 - 财政年份:2022
- 资助金额:
$ 31.47万 - 项目类别:
Targeting testis-specific ubiquitin-proteasome pathways for male contraception
针对男性避孕的睾丸特异性泛素蛋白酶体途径
- 批准号:
10018522 - 财政年份:2019
- 资助金额:
$ 31.47万 - 项目类别:
Functional genomics and DEC-Tec to identify germ cell-specific contraceptives
功能基因组学和 DEC-Tec 鉴定生殖细胞特异性避孕药
- 批准号:
10164823 - 财政年份:2017
- 资助金额:
$ 31.47万 - 项目类别:
Targeting sperm-specific proteins during meiosis and sperm morphogenesis
在减数分裂和精子形态发生过程中靶向精子特异性蛋白
- 批准号:
9278439 - 财政年份:2017
- 资助金额:
$ 31.47万 - 项目类别:
相似海外基金
Bone Morphogenic Protein Signaling Pathways in Uterine Biology
子宫生物学中的骨形态发生蛋白信号通路
- 批准号:
8324763 - 财政年份:1994
- 资助金额:
$ 31.47万 - 项目类别:
Bone Morphogenic Protein Signaling Pathways in Uterine Biology
子宫生物学中的骨形态发生蛋白信号通路
- 批准号:
8495780 - 财政年份:1994
- 资助金额:
$ 31.47万 - 项目类别:
Bone Morphogenic Protein Signaling Pathways in Uterine Biology
子宫生物学中的骨形态发生蛋白信号通路
- 批准号:
8791403 - 财政年份:1994
- 资助金额:
$ 31.47万 - 项目类别:
Bone Morphogenic Protein Signaling Pathways in Uterine Biology
子宫生物学中的骨形态发生蛋白信号通路
- 批准号:
8150354 - 财政年份:1994
- 资助金额:
$ 31.47万 - 项目类别:
Bone Morphogenic Protein Signaling Pathways in Uterine Biology
子宫生物学中的骨形态发生蛋白信号通路
- 批准号:
8291137 - 财政年份:1994
- 资助金额:
$ 31.47万 - 项目类别: